SHPGY Related New Coverage
-
Leerink Swann Starts Shire plc (SHPGY) at Market Perform; Growth Already Priced In; Wait for Better Entry
-
William Blair Starts Shire plc (SHPGY) at Market Perform
-
Citadel Securities Starts Shire plc (SHPGY) at Add, Sets $97 Price Target
-
Susquehanna Starts Shire plc (SHPGY) at Neutral
-
Susquehanna Starts AGN, MRX, WCRX at Positive; FRX at Negative; CEPH, ENDP, KG, SHPGY at Neutral
-
RBS Starts Shire (SHPGY) at Sell
-
Hapoalim Securities Initiates Coverage on Genzyme (GENZ) with a Hold; Pipeline Promising, But Near-Term Competition
-
Credit Suisse Initiates Coverage on Shire plc (SHPGY) with a Neutral
-
Leerink Swann Initiates Coverage on Shire Pharma (SHPGY) with an Overweight; Emerging Growth Story
-
SunTrust Initiates Coverage on Several Drug Manufacturers & Suppliers
-
Lazard Capital Starts Shire Limited (SHPGY) at Hold
-
Oppenheimer Initiates Coverage on Shire plc (SHPGY) with an Underperform
-
Jefferies & Co Initiates Coverage on Shire (SHPGY) with an Underperform
-
Baird Resumes Coverage on Drug Manufacturers
-
Caris & Co Initiates Coverage on Shire Ltd. (SHPGY) with an Above Average Rating.
-
Friedman Billings Re-initiates Coverage on SHIRE (SHPGY) with an Outperform
-
Banc of America Starts Shire plc (SHPGY) at Buy
-
Prudential Starts Shire Pharma (SHPGY) at Neutral Weight
-
Cowen initiates coverage on Shire (SHPGY) at Outperform
-
Baird Initiates SHPGY
-
WR Hambrecht Starts SHPGY at Buy; Sees BRL Settlement on Adderall XR
-
Smith Barney Starts SHPGY At Buy
Back to SHPGY Stock Lookup
